Shares in Ocular Therapeutix (NSDQ:OCUL) rose this week after the company topped expectations on Wall Street with its second-quarter financial results.
The Bedford, Mass.-based company posted a net loss of -$13.8 million on sales of $648,000 for the three months ended June 30, representing sales growth of 48% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Ocular Therapeutix beats The Street with Q2 results appeared first on MassDevice.